Spots Global Cancer Trial Database for Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia

Official Title: Development of Novel Therapeutics for AMKL

Study ID: NCT01139307

Conditions

Leukemia

Interventions

cell culture procedure

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.

Detailed Description: OBJECTIVES: * Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia. OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.